Zanubrutinib vs. ibrutinib

Zanubrutinib (Zanubrutinib) and ibrutinib (Ibrutinib) are both in a class of drugs called "brutinib", which belong to a class of drugs called Bruton tyrosine kinase (BTK) inhibitors. These drugs are widely used to treat B-cell lymphoma and chronic lymphocytic leukemia. Zanubrutinib and ibrutinib have similar mechanisms in that they both work by inhibiting the activity of a specific B cell enzyme, BTK. BTK is a key signaling molecule that plays an important role in the growth and proliferation of B cells. By inhibiting BTK, these drugs block the growth and spread of B-cell tumors. Although both zanubrutinib and ibrutinib are BTK inhibitors, they have slightly different chemical structures, with zanubrutinib thought to bind to BTK more strongly in the body and with greater selectivity, meaning it may have better efficacy and fewer side effects.